Kalaris Therapeutics (KLRS) Income Statement: Revenue & Earnings

Kalaris Therapeutics Income Statement Analysis

Revenue, earnings, and profit margins in millions USD

Scale:

Scroll to see more

Kalaris Therapeutics, Inc. income statement - Annual data in millions USD
Breakdown	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Revenue & Gross Profit
Revenue	0.00	0.00	0.00	0.00	0.00
Cost of Revenue	0.00	0.00	0.00	0.00	0.00
Gross Profit	0.00	0.00	0.00	0.00	0.00
Operating Expenses
Research & Development	45.04	11.71	118.87	120.74	49.66
Selling, General & Administrative	6.69	1.76	52.33	49.08	21.65
Operating Expenses	51.73	13.46	171.20	169.82	71.31
Operating Income	-51.73	-13.46	-171.20	-169.82	-71.31
Other Income/Expense
Interest Income	5.49	0.00	0.00	0.00	0.00
Interest Expense	-40.72	-1.58	-1.03	0.00	0.00
Other Income/Expense	23.28	0.34	0.35	2.45	-0.20
Income
Income Before Tax	-69.17	-14.70	-168.98	-170.96	-69.78
Income Tax Expense	0.00	-0.13	-0.27	1.01	-1.94
Net Income	-69.17	-14.70	-168.71	-171.96	-69.80
Net Income - Continuous Operations	-58.77	-14.70	-15.49	0.00	0.00
Net Income - Discontinued Operations	0.00	0.00	0.00	0.00	0.00
EBITDA	-58.77	-190.13	-170.48	-169.63	-71.24
EBIT	-51.73	-13.46	-171.20	-169.82	-71.31
Depreciation & Amortization	0.00	0.40	0.70	0.20	0.10
Earnings Per Share
Basic EPS	-10.00	-2.00	-2.00	-3.00	-3.00
Diluted EPS	-10.00	-2.00	-2.00	-3.00	-3.00
Basic Shares Outstanding	6.63	6.07	76.65	62.78	26.90
Diluted Shares Outstanding	6.63	6.07	76.65	0.00	26.90